antacids

Summary

Summary: Substances that counteract or neutralize acidity of the GASTROINTESTINAL TRACT.

Top Publications

  1. pmc Antacids and dietary supplements with an influence on the gastric pH increase the risk for food sensitization
    I Pali-Schöll
    IPP Department of Pathophysiology, Centre of Physiology, Pathophysiology and Immunology, Medical University of Vienna, Vienna, Austria
    Clin Exp Allergy 40:1091-8. 2010
  2. pmc Endoscopic gastroplication for the treatment of gastro-oesophageal reflux disease: a randomised, sham-controlled trial
    M P Schwartz
    Department of Gastroenterology, University Medical Centre, PO Box 85500, 3508 GA Utrecht, The Netherlands
    Gut 56:20-8. 2007
  3. ncbi First evidence of a possible association between gastric acid suppression during pregnancy and childhood asthma: a population-based register study
    E Dehlink
    Division of Gastroenterology and Nutrition, Children s Hospital Boston, Harvard Medical School, Boston, MA 02115, USA
    Clin Exp Allergy 39:246-53. 2009
  4. ncbi Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring: mechanistic assessment in healthy volunteers and randomised, controlled, doub
    R Sweis
    Department of Gastroenterology, Guys and St Thomas NHS Foundation Trust, London, UK
    Aliment Pharmacol Ther 37:1093-102. 2013
  5. ncbi Gastric cytoprotection beyond prostaglandins: cellular and molecular mechanisms of gastroprotective and ulcer healing actions of antacids
    Andrzej Tarnawski
    University of California, Irvine, Chief, Gastroenterology, VA Long Beach Healthcare System, 5901 E 7th Street, Long Beach, CA 90822 5201, USA
    Curr Pharm Des 19:126-32. 2013
  6. pmc An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial 'acid pocket' in symptomatic GERD patients
    M A Kwiatek
    Department of Medicine, Feinberg School of Medicine, Northwestern University, 676 St Clair Street, Chicago, IL 60611 2951, USA
    Aliment Pharmacol Ther 34:59-66. 2011
  7. ncbi The acid pocket: a target for treatment in reflux disease?
    Peter J Kahrilas
    Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Am J Gastroenterol 108:1058-64. 2013
  8. ncbi An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease
    Wout O Rohof
    Department of Gastroenterology and Hepatology, Academic Medical Centre, Amsterdam, The Netherlands
    Clin Gastroenterol Hepatol 11:1585-91; quiz e90. 2013
  9. ncbi Systematic review: Antacids, H2-receptor antagonists, prokinetics, bismuth and sucralfate therapy for non-ulcer dyspepsia
    P Moayyedi
    Gastroenterology Unit, City Hospital NHS Trust, Birmingham, UK
    Aliment Pharmacol Ther 17:1215-27. 2003
  10. ncbi Concomitant prescription of non-steroidal anti-inflammatory drugs and antacids in the outpatient setting of a medical center in taiwan: a prescription database study
    J Y Liu
    Department of Family Medicine, Taipei Veterans General Hospital, Taiwan
    Eur J Clin Pharmacol 57:505-8. 2001

Research Grants

Detail Information

Publications266 found, 100 shown here

  1. pmc Antacids and dietary supplements with an influence on the gastric pH increase the risk for food sensitization
    I Pali-Schöll
    IPP Department of Pathophysiology, Centre of Physiology, Pathophysiology and Immunology, Medical University of Vienna, Vienna, Austria
    Clin Exp Allergy 40:1091-8. 2010
    ..This can be caused by acid-suppressing medication like sucralphate, H2-receptor blockers and proton pump inhibitors, as shown in recent murine experimental and human observational studies...
  2. pmc Endoscopic gastroplication for the treatment of gastro-oesophageal reflux disease: a randomised, sham-controlled trial
    M P Schwartz
    Department of Gastroenterology, University Medical Centre, PO Box 85500, 3508 GA Utrecht, The Netherlands
    Gut 56:20-8. 2007
    ..Endoscopic treatment for gastro-oesophageal reflux disease (GORD) is rapidly emerging, but there is a great need for randomised controlled trials to evaluate the efficacy...
  3. ncbi First evidence of a possible association between gastric acid suppression during pregnancy and childhood asthma: a population-based register study
    E Dehlink
    Division of Gastroenterology and Nutrition, Children s Hospital Boston, Harvard Medical School, Boston, MA 02115, USA
    Clin Exp Allergy 39:246-53. 2009
    ..Recent data in mice suggest that acid suppression during pregnancy yields offspring with type 2 T helper-dominant immunity, suggesting a predisposition for allergy...
  4. ncbi Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring: mechanistic assessment in healthy volunteers and randomised, controlled, doub
    R Sweis
    Department of Gastroenterology, Guys and St Thomas NHS Foundation Trust, London, UK
    Aliment Pharmacol Ther 37:1093-102. 2013
    ..Alginates form a raft above the gastric contents, which may suppress gastro-oesophageal reflux; however, inconsistent effects have been reported in mechanistic and clinical studies...
  5. ncbi Gastric cytoprotection beyond prostaglandins: cellular and molecular mechanisms of gastroprotective and ulcer healing actions of antacids
    Andrzej Tarnawski
    University of California, Irvine, Chief, Gastroenterology, VA Long Beach Healthcare System, 5901 E 7th Street, Long Beach, CA 90822 5201, USA
    Curr Pharm Des 19:126-32. 2013
    ..defense, injury, protection and ulcer healing with a focus on mucosal protective and ulcer healing actions of antacids. The gastric mucosa is continuously exposed to a variety of noxious factors, both endogenous such as: 0...
  6. pmc An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial 'acid pocket' in symptomatic GERD patients
    M A Kwiatek
    Department of Medicine, Feinberg School of Medicine, Northwestern University, 676 St Clair Street, Chicago, IL 60611 2951, USA
    Aliment Pharmacol Ther 34:59-66. 2011
    ..By creating a low density gel 'raft' that floats on top of gastric contents, alginate-antacid formulations may neutralise the 'acid pocket'...
  7. ncbi The acid pocket: a target for treatment in reflux disease?
    Peter J Kahrilas
    Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Am J Gastroenterol 108:1058-64. 2013
    ....
  8. ncbi An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease
    Wout O Rohof
    Department of Gastroenterology and Hepatology, Academic Medical Centre, Amsterdam, The Netherlands
    Clin Gastroenterol Hepatol 11:1585-91; quiz e90. 2013
    ..We studied the location of an alginate formulation in relation to the acid pocket and the corresponding effects on reflux parameters and acid pocket positioning in patients with gastroesophageal reflux disease (GERD)...
  9. ncbi Systematic review: Antacids, H2-receptor antagonists, prokinetics, bismuth and sucralfate therapy for non-ulcer dyspepsia
    P Moayyedi
    Gastroenterology Unit, City Hospital NHS Trust, Birmingham, UK
    Aliment Pharmacol Ther 17:1215-27. 2003
    Evidence for the effectiveness of antacids, histamine-2 receptor antagonists, bismuth salts, sucralfate and prokinetic therapy in non-ulcer dyspepsia is conflicting.
  10. ncbi Concomitant prescription of non-steroidal anti-inflammatory drugs and antacids in the outpatient setting of a medical center in taiwan: a prescription database study
    J Y Liu
    Department of Family Medicine, Taipei Veterans General Hospital, Taiwan
    Eur J Clin Pharmacol 57:505-8. 2001
    OBJECTIVE: Although antacids were ineffective in preventing serious gastrointestinal complications caused by non-steroidal anti-inflammatory drugs (NSAIDs), many physicians in Taiwan still prescribe antacids concomitantly with NSAIDs...
  11. ncbi The impact of aluminium in acid-suppressing drugs on the immune response of BALB/c mice
    R Brunner
    Department of Pathophysiology, Medical University of Vienna, Vienna, Austria
    Clin Exp Allergy 37:1566-73. 2007
    ..This may be due to hindered peptic digestion, caused by an elevation of the gastric pH. Additionally, it is known that aluminium-linked antigens lead to an increased probability of sensitization...
  12. ncbi Effects of a single low dose of ranitidine and effervescent antacids on intragastric acidity in healthy volunteers
    Rafael Améndola
    Investigación Gastroenterológica Asociación Civil, Buenos Aires, Argentina
    Acta Gastroenterol Latinoam 37:231-7. 2007
    ..Our aim was to determine the effect of the combined intake of both, of a low dose ranitidine (OTC) and 5 g of antacid on gastric pH...
  13. pmc Pharmacology of proton pump inhibitors
    Jai Moo Shin
    Membrane Biology, David Geffen School of Medicine, University of California at Los Angeles, Room 324, Building 113, 11301 Wilshire Boulevard, Los Angeles, CA 90073, USA
    Curr Gastroenterol Rep 10:528-34. 2008
    ..PPIs with longer half-life promise to improve acid suppression. All PPIs give excellent healing of peptic ulcers and produce good results in reflux esophagitis. PPIs combined with antibiotics eradicate Helicobacter pylori...
  14. pmc The role of protein digestibility and antacids on food allergy outcomes
    Eva Untersmayr
    Department of Pathophysiology, Center of Physiology, Pathophysiology, and Immunology, Medical University of Vienna, Vienna, Austria
    J Allergy Clin Immunol 121:1301-8; quiz 1309-10. 2008
    ..Thus antiulcer agents impeding gastric protein digestion have a major effect on the sensitization and effector phase of food allergy...
  15. ncbi Aluminium per se and in the anti-acid drug sucralfate promotes sensitization via the oral route
    R Brunner
    Department of Pathophysiology, Medical University of Vienna, Vienna, Austria
    Allergy 64:890-7. 2009
    ..These anti-acids have been shown to cause sensitization to food proteins via elevation of the gastric pH. The aim of this study was to assess the oral adjuvant properties of ALUM, alone or contained in SUC, in a BALB/c mouse model...
  16. ncbi Application of a data-mining technique to analyze coprescription patterns for antacids in Taiwan
    Tzeng Ji Chen
    Department of Family Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
    Clin Ther 25:2453-63. 2003
    Although antacids are popular drugs with a long history of use, their true utilization patterns-including over-the-counter use-have rarely been documented...
  17. ncbi Antacid medication inhibits digestion of dietary proteins and causes food allergy: a fish allergy model in BALB/c mice
    Eva Untersmayr
    Department of Pathophysiology, University of Vienna, AKH 3Q, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    J Allergy Clin Immunol 112:616-23. 2003
    ..Approximately 10% of the adult population uses antacids for the treatment of dyspeptic disorders, drugs that hinder peptic digestion...
  18. ncbi Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids
    C A Peloquin
    Department of Medicine, National Jewish Medical and Research Center, School of Pharmacy, University of Colorado, Denver 80206, USA
    Chest 115:12-8. 1999
    Determine the intrasubject and intersubject variability in, and the effects of food or antacids on, the pharmacokinetics of rifampin (RIF).
  19. ncbi Evaluation of the buffering capacity of powdered cow's, goat's and soy milk and non-prescription antacids in the treatment of non-ulcer dyspepsia
    D Lutchman
    School of Pharmacy and Pharmacology, University of KwaZulu Natal, Durban, South Africa
    S Afr Med J 96:57-61. 2006
    ..Treatment choice commonly includes over the counter medicines and home remedies, e.g. milk...
  20. ncbi Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients
    Y Takeda
    Department of Respiratory Medicine, International Medical Center of Japan, Tokyo, Japan
    Int J Cancer 92:269-75. 2001
    ..Risk factors statistically associated with delayed diarrhea include advanced age and the use of CPT-11 without OA and CD...
  21. ncbi Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies
    Daphne D Williams
    GlaxoSmithKline, Research Triangle Park, North Carolina, USA
    Clin Ther 31:764-76. 2009
    ..Eltrombopag is the first orally self-administered, small-molecule, nonpeptide thrombopoietin receptor agonist for the treatment of chronic idiopathic thrombocytopenic purpura...
  22. ncbi Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults
    C M Rubino
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, 43 British American Boulevard, Latham, NY 12110, USA
    Pulm Pharmacol Ther 22:279-85. 2009
    ..single-dose crossover study, the pharmacokinetics (PK) of pirfenidone were investigated with or without food and antacids in healthy adult volunteers...
  23. ncbi Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids
    M Zhu
    Department of Medicine, National Jewish Medical and Research Center, Denver, Colorado 80206, USA
    Pharmacotherapy 21:891-7. 2001
    STUDY OBJECTIVES: To determine the effect of a high-fat meal, orange juice, and antacids on absorption of a single oral dose of cycloserine and to estimate its population pharmacokinetic parameters...
  24. ncbi Aluminum-containing antacids as a cause of idiopathic Parkinson's disease
    E Altschuler
    UC San Diego School of Medicine, La Jolla, CA 92092 0606, USA
    Med Hypotheses 53:22-3. 1999
    ..Aluminum is thought to be a cellular toxin. Here I suggest that aluminum, and in particular aluminum-containing antacids may contribute to the pathogenesis of idiopathic PD.
  25. pmc Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids
    Paul Snell
    Department of Research and Development, Roche Products Ltd, Welwyn Garden City, Hertfordshire, UK
    Br J Clin Pharmacol 54:372-7. 2002
    ....
  26. ncbi Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids
    C A Peloquin
    Department of Medicine, National Jewish Medical and Research Center, Denver, Colorado 80206, USA
    Int J Tuberc Lung Dis 3:703-10. 1999
    To determine the intra- and intersubject variability in and the effects of food or antacids on the pharmacokinetics of isoniazid (INH).
  27. ncbi Comparative palatability of 22 liquid antacids
    M E Temple
    College of Pharmacy, The Ohio State University, Columbus, USA
    Aliment Pharmacol Ther 14:421-5. 2000
    To compare the palatability, acid neutralizing capability, and costs of different antacids.
  28. ncbi Impact of food and antacids on the pharmacokinetics of anti-tuberculosis drugs: systematic review and meta-analysis
    M Y Lin
    Department of Pharmacy, Tian Sheng Memorial Hospital, Tong Kang, Ping Tong County, Taiwan, Republic of China
    Int J Tuberc Lung Dis 14:806-18. 2010
    To compare the effects of food and antacids on the bioavailability of first-line anti-tuberculosis drugs.
  29. ncbi Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial
    Corine J Van Marrewijk
    Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
    Lancet 373:215-25. 2009
    ..We compared step-up and step-down treatment strategies for initial management of patients with new onset dyspepsia in primary care...
  30. ncbi How do primary care physicians use long-term acid suppressant drugs? A population-based analysis of Dutch general practices
    G J B Hurenkamp
    Dept of General Practice, Academic Medical Center, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands
    J Fam Pract 51:241-5. 2002
    ..We investigated the magnitude of long-term prescription of acid suppressant drugs in general practice and the frequency and means of confirming the primary working diagnosis...
  31. ncbi Arrest of chronic acid suppressant drug use after successful Helicobacter pylori eradication in patients with peptic ulcer disease: a six-month follow-up study
    G J Hurenkamp
    Department of General Practice, Academic Medical Centre, Meibergdreef 9, Amsterdam, The Netherlands
    Aliment Pharmacol Ther 15:1047-54. 2001
    ..pylori eradication leads to relief of dyspepsia and the subsequent arrest or tapering of acid-suppressant drug therapy, or to an aggravation of acid-related dyspepsia requiring more acid-suppressant drug intake...
  32. ncbi [Continuation of acid suppression therapy after H. pylori eradication]
    Morio Takahashi
    Department of Gastroenterology and Hepatology, Koshigaya Hospital, Dokkyo University of Medicine
    Nihon Rinsho 60:531-5. 2002
  33. ncbi Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and stool test for Helicobacter pylori infection
    Luigi Gatta
    Department of Internal Medicine and Gastroenterology, University of Bologna, S Orsola Halpighi Hospital, Bologna, Italy
    Am J Gastroenterol 99:823-9. 2004
    ....
  34. ncbi [GERD. Introduction]
    Tsutomu Chiba
    Department of Gastroenterology and Hepatology, Graduate School of Medicine and Faculty of Medicine, Kyoto University
    Nihon Rinsho 62:1411-4. 2004
    ..Thus, an effort for improving both sensitivity and specificity of the diagnosing method for NERD is required. In any event, it should be kept in mind that pathophysiology of GERD is quite different between Western and Japanese patients...
  35. ncbi [PPI: new strategies for GERD]
    Etsuo Hoshino
    Department of Internal Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research
    Nihon Rinsho 62:1570-6. 2004
    ..A small number of GERD patients resistant to PPI therapy may be due to nocturnal acid breakthrough (NAB) or rapid metabolism of PPI (extensive metabolizer for CYP2C19)...
  36. ncbi Acid reflux and gastro-oesophageal reflux disease
    Alan R Watson
    University Hospital, Queen s Medical Centre, Nottingham, UK
    Br J Community Nurs 9:326-30. 2004
    ..This article describes the symptoms and diagnosis of acid reflux and GORD, and reviews currently available treatments ranging from lifestyle modification to surgery...
  37. ncbi [Eradication of Helicobacter pylori and use of antisecretory drugs--a population based study]
    Annmarie Touborg Lassen
    Odense Universitetshospital, medicinsk gastroenterologisk afdeling S
    Ugeskr Laeger 166:3405-7. 2004
  38. ncbi Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis
    W J Bochenek
    Clinical Research and Development, Wyeth Research, Collegeville, PA, USA
    Aliment Pharmacol Ther 20:1105-14. 2004
    ..Effective symptom control is a primary concern of most heartburn suffers...
  39. ncbi [GERD/reflux esophagitis]
    Michio Hongo
    Department of Comprehensive Medicine, Tohoku University Hospital
    Nihon Rinsho 60:608-13. 2002
  40. ncbi [Treatment of gastroesophageal reflux in pregnant women]
    Jan G Hatlebakk
    Medisinsk avdeling, Haukeland Universitetsykehus, 5021 Bergen
    Tidsskr Nor Laegeforen 124:797-8. 2004
  41. ncbi Predictive factors of the long-term outcome in reflux esophagitis in a low-prevalence gastroesophageal reflux disease region
    C S Chang
    Division of Gastroenterology, Taichung Veterans General Hospital, Taichung, Taiwan, ROC
    Scand J Gastroenterol 38:1131-5. 2003
    ..In this study the outcome and the specific prognostic indicators associated with outcome in patients were assessed retrospectively, 7 years after diagnosis of esophagitis...
  42. ncbi Medical management of nocturnal symptoms of gastro-oesophageal reflux disease in the elderly
    Samer Gawrieh
    Division of Gastroenterology and Hepatology, Department of Medicine, MCW Dysphagia Institute, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA
    Drugs Aging 20:509-16. 2003
    ..Histamine H(2) receptor antagonists are suitable for mild-to-moderate ENRD. Antacids and lifestyle modifications may be incorporated into the management as adjuncts to more potent and durable ..
  43. ncbi [As-needed treatment with gastric acid inhibitors in gastroesophageal reflux disease]
    A C Poen
    Meander Medisch Centrum, afd Interne Geneeskunde en Gastroenterologie, Amersfoort
    Ned Tijdschr Geneeskd 147:1632-6. 2003
    ..All antacids can in principle be used for on-demand treatment; for type 3 treatment, antacids with a rapid onset of action are ..
  44. ncbi Maintenance treatment is not necessary after Helicobacter pylori eradication and healing of bleeding peptic ulcer: a 5-year prospective, randomized, controlled study
    Chen Chiung Liu
    Division of Gastroenterology, Department of Internal Medicine, Cathay General Hospital, Taipei, Taiwan
    Arch Intern Med 163:2020-4. 2003
    ..The aim of this 5-year, prospective, randomized, controlled study was to investigate the role of long-term maintenance therapy after successful H pylori eradication and healing of bleeding ulcers...
  45. ncbi Current trends in the treatment of upper gastrointestinal disease
    George Sachs
    Geffen School of Medicine at UCLA and GWLA Health Center, Los Angeles, USA
    Best Pract Res Clin Gastroenterol 16:835-49. 2002
    ..Research continues in an attempt to find improved means of acid control and better methods for the eradication of H. pylori based on unique proteins expressed by the organism to resist gastric acidity...
  46. ncbi Gastroesophageal reflux disease: current treatment approaches
    Wendy Biddle
    Director 11:155-9. 2003
  47. ncbi [Heartburn without esophagitis. Symptoms more important than the finding?]
    H S Fuessl
    MMW Fortschr Med 145:4-6. 2003
  48. ncbi [Stress ulcer]
    Kimitoshi Kato
    Third Department of Internal Medicine, Nihon University School of Medicine
    Nihon Rinsho 60:619-24. 2002
  49. ncbi Ambulatory intragastric pH monitoring: clinical laboratory to clinical practice
    Phillip O Katz
    Division of Gastroenterology and Nutrition, Albert Einstein Medical Center, Philadelphia, Pennsylvania, USA
    Rev Gastroenterol Disord 3:S3-9. 2003
    ..These laboratory experiences can be used in clinical practice to aid in management of patients with gastroesophageal reflux disease...
  50. ncbi [Treatment of laryngeal granuloma with anti-extraesophageal reflux medication]
    J P Benaixa
    Servicio de Otorrinolaringologia, Hospitales Universitarios Virgen del Rocio, Sevilla
    Acta Otorrinolaringol Esp 54:501-5. 2003
    ..To asses the role of Gastroesophageal reflux in the genesis of laryngeal granulomas...
  51. ncbi [The treatment of peptic ulcer in elderly CRF patients]
    Hitoshi Iwabuchi
    Department of Internal Medicine, Tsurumi Westside Hospital
    Nihon Rinsho 60:1601-5. 2002
    ..It is needless to say that special attentions should be always paid for doses, intervals or durations in any drugs prescribed for elderly CRF patients because of lower renal metabolic clearance rates for drugs...
  52. ncbi On-demand and intermittent therapy for gastro-oesophageal reflux disease: economic considerations
    John M Inadomi
    VA Center for Practice Management and Outcomes Research and the University of Michigan Medical Center, Ann Arbor, Michigan 48105, USA
    Pharmacoeconomics 20:565-76. 2002
    ..b>Antacids, alginates, topically active agents, histamine(2)-receptor antagonists, and proton pump inhibitors have all ..
  53. ncbi Gastroesophageal reflux disease--state of the art
    P O Katz
    Graduate Hospital, MCP-Hahnemann School of Medicine, Philadelphia, PA, USA
    Rev Gastroenterol Disord 1:128-38. 2001
    ..Endoscopic therapy for reflex should be considered as an experimental technology needing continuing evaluation...
  54. ncbi Therapeutic approaches to reflux disease, focusing on acid secretion
    Yoshikazu Kinoshita
    Department of Internal Medicine II, Shimane Medical University, 89 1 Enya cho, Izumo 693 8501, Japan
    J Gastroenterol 38:13-9. 2003
    ..For these patients, addition of H2RAs to PPIs can be useful for controlling GERD, at least for short-term treatment. For long-term control of such cases, further studies are necessary...
  55. ncbi Heartburn in primary care: problems below the surface
    Gerald Holtmann
    Division of Internal Medicine, Department of Gastroenterology and Hepatology, University of Essen, Essen, Germany
    J Gastroenterol 39:1027-34. 2004
    ..This review discusses the symptoms and risk factors associated with GERD, possible links to Helicobacter pylori infection, and effective treatment strategies within a primary care setting...
  56. ncbi [Is the successful eradication of Helicobacter pylori sufficient for the healing of peptic ulcer?]
    Istvan Pregun
    Semmelweis Egyetem, Általános Orvostudományi Kar, II Belgyógyászati Klinika
    Orv Hetil 147:435-9. 2006
    ..There are less data available concerning gastric ulcer: successful eradication is also essential to ulcer healing and to avoid relapse, however it seems that post-eradication PPI therapy might be beneficial...
  57. ncbi Review article: treatment for gastro-oesophageal reflux disease--lifestyle advice and medication
    Y Kinoshita
    Department of Gastroenterology and Hepatology, Shimane University School of Medicine, Shimane 693 8501, Japan
    Aliment Pharmacol Ther 20:19-23. 2004
    ..Pharmacological therapy is, however, usually also required for effective symptom relief. While antacids and histamine H(2)-receptor antagonists have a role in treating mild GERD, effective relief of many cases of ..
  58. ncbi Helicobacter pylori seropositivity predicts outcomes of acid suppression therapy for laryngopharyngeal reflux symptoms
    Nobuhiko Oridate
    Department of Otolaryngology Head and Neck Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan
    Laryngoscope 116:547-53. 2006
    ..The effects of H. pylori infection on outcomes of acid suppression therapy have not been studied...
  59. ncbi Gastro-oesophageal reflux disease
    Paul Moayyedi
    Department of Medicine, Division of Gastroenterology, McMaster University Medical Centre, Hamilton, ON, Canada
    Lancet 367:2086-100. 2006
    ..The role of endoscopic therapy is uncertain. Anti-reflux surgery is probably as effective as PPI therapy although there is a low operative mortality and morbidity...
  60. ncbi Acid suppressive therapy use on an inpatient internal medicine service
    Co Q D Pham
    Faculty of Pharmacy, University of Montreal, Quebec, Canada
    Ann Pharmacother 40:1261-6. 2006
    ..Use of acid suppressant medications has increased in both frequency and breadth in recent years. Data have indicated that questionable use of acid suppressants for non-accepted indications is common...
  61. ncbi [Dosaging of proton pumps inhibitors]
    Odd Brørs
    Seksjon for klinisk farmakologi og toksikologi, Klinisk kjemisk avdeling, Ulleval universitetssykehus, 0407 Oslo
    Tidsskr Nor Laegeforen 126:2397-9. 2006
  62. ncbi Role of gastroesophageal reflux symptoms in exacerbations of COPD
    Ivan E Rascon-Aguilar
    University of Florida Health Science Center Jacksonville, Division of Gastroenterology, 4555 Emerson Expressway, Suite 300, Jacksonville, FL 32207, USA
    Chest 130:1096-101. 2006
    ..The aims of this investigation were to determine the prevalence of gastroesophageal reflux (GER) symptoms in COPD patients and the effect of GER on the rate of exacerbations of COPD per year...
  63. ncbi The management of upper gastrointestinal symptoms: is endoscopy indicated?
    Anne E Duggan
    Med J Aust 186:166-7. 2007
  64. ncbi Gastroesophageal reflux disease, acid suppression, and Mycobacterium avium complex pulmonary disease
    Rachel M Thomson
    MBBS, Department of Thoracic Medicine, The Prince Charles Hospital, Rode Rd, Chermside, QLD, Australia
    Chest 131:1166-72. 2007
    ....
  65. ncbi [Pharmacological efficacy of bismuth tripotassium dicitrate in peptic ulcer]
    Iu B Belousov
    Ter Arkh 79:58-66. 2007
  66. ncbi [Dyspepsia and reflux. Systematic literature review from SBU]
    Christer Staël von Holstein
    Kirurgiska kliniken, Universitetssjukhuset Lund
    Lakartidningen 104:1414-7. 2007
  67. ncbi Appropriate management of symptomatic GORD in primary care: has expert opinion changed between 2001 and 2005?
    Jan Tack
    Department of Internal Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Acta Gastroenterol Belg 70:171-6. 2007
    ..To determine current opinions of clinical experts on the appropriate management of symptomatic GORD in primary care, and to compare these opinions with those from a similar study conducted in 2001...
  68. ncbi [Modern attitude towards management of laryngopharyngeal form of gastroesophageal reflux disease. Lithuanian clinical practice guidelines for adults]
    Nora Siupsinskiene
    Department of Otorhinolaryngology, Kaunas University of Medicine, Kaunas, Lithuania
    Medicina (Kaunas) 43:832-9. 2007
    ..Combined therapy for nonresponders is described. Algorithm for stopping the medication is recommended. These recommendations may provide an efficient and economical approach to the management of this problem...
  69. pmc Medical therapy of gastroesophageal reflux disease in secondary and tertiary care settings
    G N Tytgat
    Department of Gastroenterology and Hepatology, University of Amsterdam, Academic Medical Center, The Netherlands
    Yale J Biol Med 72:219-26. 1999
    ..pylori infected individuals. Optimization of individualized therapy will require more potent and more precisely targeted motility modulating drugs and superior acid/peptic inhibiting pharmaceuticals...
  70. ncbi [PPI plus bismuth-based quintuple therapy]
    Ken Kimura
    Kimura GE Clinic
    Nihon Rinsho 63:452-8. 2005
  71. ncbi A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy
    N Magaret
    Department of Medicine, Sections of Gastroenterology, Oregon Health Sciences University, Portland, OR 97201, USA
    Dig Dis 19:174-8. 2001
    ..To determine whether LAC or LBMT is as effective for retreating patients failing non-metronidazole-containing regimens requires further study...
  72. ncbi Treatment of gastric hemorrhage by pulverized omeprazole and antacid--concomitant administration via a nasogastric tube
    T Yamaguchi
    Department of Hospital Pharmacy, Isahaya Ryoiku Center, Nagasaki, Japan
    Int J Clin Pharmacol Ther 42:594-6. 2004
    ..Thus, administration of pulverized omeprazole concomitantly with antacid via a fine nasogastric tube may provide a novel approach for the treatment of chronic GER in pediatric patients with SMID...
  73. ncbi The effect of acid suppression on sleep patterns and sleep-related gastro-oesophageal reflux
    W C Orr
    Lynn Institute for Healthcare Research, Oklahoma City, OK, USA
    Aliment Pharmacol Ther 21:103-8. 2005
    ..Several studies have demonstrated that night-time gastro-oesophageal reflux affects sleep quality, and thereby impairs daytime functioning...
  74. ncbi Rebound acid hypersecretion after long-term inhibition of gastric acid secretion
    R Fossmark
    Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Aliment Pharmacol Ther 21:149-54. 2005
    ..Rebound acid hypersecretion develops after the use of acid inhibitors...
  75. ncbi The pharmacological management of gastroesophageal reflux disease
    R C Lowe
    Boston University School of Medicine, Boston Medical Center, Boston, USA
    Minerva Gastroenterol Dietol 50:227-37. 2004
    ..A treatment schema for GERD based on presenting symptoms is outlined, promoting a stepwise approach to the appropriate use of antisecretory therapy...
  76. ncbi PPI use in the OTC era: who to treat, with what, and for how long?
    John M Inadomi
    Division of Gastroenterology, Department of Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
    Clin Gastroenterol Hepatol 3:208-15. 2005
    ..The availability of over-the-counter (OTC) and generic PPIs provides consumers with options other than antacids and histamine 2 -receptor antagonists (H2RAs) for self-medication of heartburn and acid regurgitation...
  77. pmc Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study
    P Malfertheiner
    Department of Gastroenterology, Hepatology, and Infectious Diseases, Otto von Guericke University, Magdeburg, Germany
    Gut 54:746-51. 2005
    ..We report on factors influencing endoscopic healing and symptom resolution during the acute treatment phase...
  78. ncbi Heartburn: issues in patient management. A roundtable discussion
    Goutham Rao
    University of Pittsburgh School of Medicine, PA, USA
    J Fam Pract 54:s1-6. 2005
  79. ncbi Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance o
    F Pace
    Department of Gastroenterology, Luigi Sacco University Hospital, Via G B Grassi, 74, 20157 Milan, Italy
    Dig Liver Dis 37:741-50. 2005
    ..However, such studies have been conducted as superiority studies but interpreted as equivalence ones...
  80. ncbi Acid-suppressing drugs and gastroesophageal reflux disease as risk factors for acute pancreatitis--results from a Swedish Case-Control Study
    Anders Sundström
    Medical Products Agency, Uppsala, Sweden
    Pharmacoepidemiol Drug Saf 15:141-9. 2006
    ..To study risk factors for acute pancreatitis, here with emphasis on gastro-intestinal diseases and their treatments...
  81. ncbi A long-term comparison of plication configurations for endoluminal gastroplication: circumferential versus helical
    Richard E Davis
    Department of Surgery, Creighton University School of Medicine, 601 N 30th Street, Omaha, NE 68131, USA
    J Clin Gastroenterol 39:869-76. 2005
    ..To determine the long-term efficacy of endoluminal gastroplication (ELGP) and the most effective plication configuration...
  82. ncbi Treatment of gastroesophageal reflux disease
    Michael Pettit
    Clinical Pharmacy Unit, Royal Sussex Country Hospital, University of Brighton, Eastern Road, Brighton, BN2 5BE, UK
    Pharm World Sci 27:432-5. 2005
    ..Published manuscripts were identified from Medline. The articles were then screened for relevance prior to inclusion in the review...
  83. ncbi Gastric acid suppression and the risk of enteric peritonitis in peritoneal dialysis patients
    Sharon J Nessim
    Division of Nephrology, University of Toronto, Toronto, Ontario, Canada
    Perit Dial Int 28:246-51; discussion 236-7. 2008
    ..The objective of this study was to determine, using a larger patient population, whether gastric acid suppressants are associated with an increased risk of EP...
  84. ncbi Maintenance therapy for duodenal ulcer: a randomized controlled comparison of seven forms of treatment
    W M Hui
    Department of Medicine, University of Hong Kong, Queen Mary Hospital
    Am J Med 92:265-74. 1992
    We performed a randomized controlled trial to compare the efficacy of seven forms of maintenance treatment of duodenal ulcer, including a mealtime regimen of antacids.
  85. ncbi Delavirdine: clinical pharmacokinetics and drug interactions
    J Q Tran
    Agouron Pharmaceuticals, Inc, A Pfizer Company, La Jolla, California, USA
    Clin Pharmacokinet 40:207-26. 2001
    ..Reduction in gastric acidity (pH > 3) decreases the extent of delavirdine absorption, so administration of antacids and the buffered formulations of didanosine should be separated from that of delavirdine by at least 1 hour...
  86. pmc Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole, or ciprofloxacin
    Bharat D Damle
    Clinical Discovery, Bristol Myers Squibb Pharmaceutical Research Institute, Bristol Myers Squibb Company, Princeton, New Jersey 08543, USA
    Antimicrob Agents Chemother 46:385-91. 2002
    ..can result in a significant decrease in the oral absorption of certain drugs because of interactions with antacids. An enteric formulation of didanosine is unlikely to cause such drug interactions because it lacks antacids...
  87. ncbi Gastroesophageal reflux disease: pathophysiology and pharmacology overview
    E Z Dajani
    International Drug Development Consultants IDDC Corporation, Long Grove, Illinois 60047 9532, USA
    J Assoc Acad Minor Phys 11:7-11. 2000
    ..b>Antacids, prokinetics, and gastric antisecretory agents are the principal drugs currently used to treat GERD in ..
  88. ncbi Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004
    David Armstrong
    Division of Gastroenterology, McMaster University, Hamilton
    Can J Gastroenterol 19:15-35. 2005
    ..Since the last Canadian Consensus Conference in 1996, GERD management has evolved substantially...
  89. ncbi Review article: alginate-raft formulations in the treatment of heartburn and acid reflux
    K G Mandel
    SmithKline Beecham Consumer Health Care, Parsippany, NJ 07054, USA
    Aliment Pharmacol Ther 14:669-90. 2000
    ..of heartburn and oesophagitis, and appear to act by a unique mechanism which differs from that of traditional antacids. In the presence of gastric acid, alginates precipitate, forming a gel...
  90. ncbi Impact on human health of Salmonella spp. on pork in The Netherlands and the anticipated effects of some currently proposed control strategies
    B R Berends
    Department of the Science of Food of Animal Origin, Faculty of Veterinary Medicine, Utrecht University, The Netherlands
    Int J Food Microbiol 44:219-29. 1998
    ..as neoplasms or diabetes mellitus (1200 cases/100,000 pyar); (2) persons with achlorhydria or who excessively use antacids (1100 cases/100,000 pyar); (3) persons who have recently been treated with antibiotics that disturb the normal ..
  91. ncbi A critical review of the fluoroquinolones: focus on respiratory infections
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Drugs 62:13-59. 2002
    ..Drug interactions are limited; however, all fluoroquinolones interact with metal ion containing drugs (eg. antacids)...
  92. ncbi Pharmacokinetic investigation of a nicotine sublingual tablet
    L Molander
    Department of Clinical Pharmacology, Pharmacia and Upjohn Consumer Healthcare, Lund, Sweden
    Eur J Clin Pharmacol 56:813-9. 2001
    ..To evaluate the pharmacokinetics of a new 2-mg nicotine sublingual tablet under varying conditions of use...
  93. ncbi Hospital-acquired diarrhea in adults: a prospective case-controlled study in Mexico
    M Zaidi
    Department of Infectious Diseases, , , Mexico City, Mexico
    Infect Control Hosp Epidemiol 12:349-55. 1991
    ..01). Multivariate analysis showed enteral feeding, recent enemas, presence of Candida species, use of antacids/H2-blockers, and presence of nasogastric tubes as significant risk factors for nosocomial diarrhea...
  94. ncbi Clinical experience with pantoprazole in gastroesophageal reflux disease
    D L Avner
    Gastroenterology, St Mark s Hospital, Salt Lake City, Utah 84124, USA
    Clin Ther 22:1169-85; discussion 1149-50. 2000
    ..Pantoprazole is a new proton pump inhibitor indicated for the treatment of erosive esophagitis associated with gastroesophageal reflux disease (GERD) and is available in both oral and intravenous (IV) formulations...
  95. ncbi Factors affecting solubility and penetration of clarithromycin through gastric mucus
    P Grubel
    Division of Gastroenterology, St Elizabeth s Medical Center of Boston, Tufts University School of Medicine, MA 02135, USA
    Aliment Pharmacol Ther 12:569-76. 1998
    ..Factors influencing the pharmacokinetics of clarithromycin in gastric mucus are poorly defined...
  96. ncbi Pharmacokinetics of para-aminosalicylic acid granules under four dosing conditions
    C A Peloquin
    Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206 2762, USA
    Ann Pharmacother 35:1332-8. 2001
    ..To determine the pharmacokinetics and relative bioavailability of para-aminosalicylic acid (PAS) granules...
  97. ncbi Current guidelines on stress ulcer prophylaxis
    M Tryba
    Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Bergmannsheil, Bochum, Germany
    Drugs 54:581-96. 1997
    ..Preventive strategies aim to reduce gastric acidity (histamine H2 receptor antagonists, antacids), strengthen mucosal defensive mechanisms (sucralfate, antacids, pirenzepine) and normalise gastric mucosal ..
  98. ncbi Diagnosis of magnesium-induced diarrhea
    K D Fine
    Department of Internal Medicine, Baylor University Medical Center, Dallas, TX 75246
    N Engl J Med 324:1012-7. 1991
    ..The purposes of this study were to establish a method for diagnosing magnesium-induced diarrhea and to apply it to patients with chronic diarrhea...
  99. ncbi Review article: treatment of mild and severe cases of GERD
    G N J Tytgat
    Academic Medical Center, Department of Gastroenterology and Hepatology, Amsterdam Zuidoost, The Netherlands
    Aliment Pharmacol Ther 16:73-8. 2002
    ..of the bed, maintaining normal weight, and avoidance of foods and drugs that precipitate symptoms, together with antacids or over-the-counter H(2) receptor antagonists (H(2)RAs)...
  100. ncbi Applying data mining techniques in the development of a diagnostics questionnaire for GERD
    Noya Horowitz
    Department of Gastroenterology and Liver Disease, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    Dig Dis Sci 52:1871-8. 2007
    ..relevant variables discriminating GERD from non-GERD patients were heartburn, regurgitation, clinical response to antacids, sour taste, and aggravation of symptoms after a heavy meal...
  101. ncbi Black tongue secondary to bismuth subsalicylate: case report and review of exogenous causes of macular lingual pigmentation
    Philip R Cohen
    University of Houston Health Center, University of Houston, Houston, TX, USA
    J Drugs Dermatol 8:1132-5. 2009
    ..The ingestion of medications, including other antacids, analgesics, antidepressants, antihypertensives and several antimicrobials has been associated with the ..

Research Grants26

  1. Hyperacidification and Pseudomonas infections in CF
    Vojo Deretic; Fiscal Year: 2006
    ..a connection between the CFTR defect and infection and inflammation in CF, and provide a basis for development of new chemotherapies using appropriately formulated antacids or inhibitors of pumps and ion channels.
  2. Accelerating Adoption of Comparative Effectiveness Research in Premature Infants
    Phillip Brian Smith; Fiscal Year: 2010
    ..enteral nutrition (affecting all infants) and the use of 6 of the 12 most common medications (antibiotics, antacids, and steroids) administered in the neonatal intensive care unit...
  3. ALUMINUM IN THE EPIDEMIOLOGY OF ALZHEIMER'S DISEASE
    AMY GRAVES; Fiscal Year: 1993
    ..In that study, the use of aluminum- containing antiperspirants and antacids was found to confer an increased relative risk of developing AD...
  4. PREDICTORS OF POSTOPERATIVE ATELECTASIS PNEUMONIA
    JO BROOKS BRUNN; Fiscal Year: 2001
    ..ventilation in the postanesthesia period, pain management, postoperative mobility, administration of H2 blockers/antacids and presence of a nasogastric tube...
  5. PHARMACOKINETICS OF ANTITUBERCULOSIS DRUGS
    Charles Peloquin; Fiscal Year: 1999
    ..Subjects will receive (a) drugs taken in the fasted state, (b) drugs taken with food, and (c) drugs taken with antacids. Population pharmacokinetic models will be constructed for each antituberculosis drug using the USC*PACK software...
  6. Magnesium and Asthma - Clinical Trials
    Judith Stern; Fiscal Year: 2004
    ..evaluate baseline Mg intake (diet, tap and bottled drinking water, vitamin-mineral supplements, laxatives, and antacids), and multiple measures of Mg status, such as total and free plasma Mg, and total and free erythrocyte Mg, and ..
  7. MBRS-SCORE Biomedical Research at J C Smith Univ
    Ruth Greene; Fiscal Year: 2006
    ..Dr. Nsoki will be investigating the interface between aluminum hydroxides used as antacids and selected molecules of life.
  8. TECHNOLOGY FOR IMPROVED ORAL DELIVERY OF ANTI-HIV DRUGS
    GLEN LEESMAN; Fiscal Year: 1992
    ..ddI is extremely unstable in the acidic conditions of the stomach. However, even when ddI is given with antacids the absorption is highly variable in humans...
  9. THE ROLE OF MYCOBACTERIA IN CROHN'S DISEASE
    David Graham; Fiscal Year: 2005
    ..The results of this study should either confirm or refute the proposed etiologic association of M. paratuberculosis and Crohn's disease as well as the identification of patients with Crohn's disease and M. paratuberculosis. ..
  10. Novel Oral Adjuvant for Dental Vaccines
    LAURA HALE; Fiscal Year: 2005
    ..abstract_text> ..
  11. Chemoprevention of IBD-Associated Colon Cancer
    Laura P Hale; Fiscal Year: 2010
    ..The proposed studies will further elucidate mechanisms that can lead to novel interventions to prevent IBD-associated colon cancers, providing great benefit to IBD patients and their families. ..
  12. Surveillance for Hepatocellular Carcinoma among HCV-infected Veterans
    Hashem El Serag; Fiscal Year: 2009
    ..Evaluating the extent and patterns of HCC surveillance is crucial in understanding diffusion (and obstacles) of this practice and in designing interventions to improve the implementation of HCC surveillance. ..
  13. An Appalchian Cervical Cancer Prevention Project
    Nancy Schoenberg; Fiscal Year: 2007
    ..abstract_text> ..
  14. Bromelain as a Biologically-Based Therapy for IBD
    LAURA HALE; Fiscal Year: 2005
    ..This research will thus strengthen the biomedical research knowledge base needed to inform the practice of complementary and alternative medicine. ..
  15. Mast Cells and IBD Pathogenesis
    LAURA HALE; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  16. GASTRIC ENTEROCHROMAFFIN-LIKE CELL IN ULCER DISEASE
    George Sachs; Fiscal Year: 2005
    ..Hence this approach will provide additional insights into mechanisms of regulation of gastric secretion and enable illuminated interpretation of the pathophysiology of peptic ulcer disease. ..
  17. MACROPHAGE DERIVED FACTOR AND LEYDIG CELL FUNCTION
    JAMES HUTSON; Fiscal Year: 2001
    ..abstract_text> ..
  18. Cancer Caregiving and the Stress Process
    Nancy Schoenberg; Fiscal Year: 2004
    ..abstract_text> ..
  19. Bromelain Proteinase Activity in IBD
    LAURA HALE; Fiscal Year: 2006
    ..They will thus strengthen the scientific knowledge base needed to inform the practice of complementary and alternative medicine. ..
  20. Laxity and Malalignment in a Large Cohort Study of OA
    Michael Nevitt; Fiscal Year: 2006
    ..abstract_text> ..
  21. Gene Expression in Barrett's Esophagus
    Hashem El Serag; Fiscal Year: 2006
    ..We present preliminary data on microarray and RT-PCRanalyses on 5 patients with BE that suggest an overactive Wnt pathway: we have also assembled the essential components of a successful study using microarrays. ..
  22. THE GASTRIC ACID PUMP AS A TARGET FOR ULCER TREATMENT
    George Sachs; Fiscal Year: 2009
    ..The results of the proposed research will further improve the agents used for the treatment of acid-related diseases and also our knowledge of the ATPase and cellular events involved in regulation of its activity. ..
  23. EVALUATION OF NIKKOMYCIN Z PHARMACOLOGY FOR TREATMENT OF UNCOMPLICATED COCCIDIODE
    David Nix; Fiscal Year: 2009
    ..By carrying out the proposed work, the investigators will resume the clinical development of nikkomycin Z as a potentially curative therapy for coccidioidomycosis so that it may become a candidate for final commercial development. ..
  24. Medication Adherence in Adolescents with Hypertension
    Renee Robinson; Fiscal Year: 2005
    ..effective assessment methods to identify risk factors for non-adherence and to improve long-term medication adherence in children and adolescents suffering from chronic renal diseases, such as hypertension or solid organ transplantation ..
  25. Fluoride Agents: Pattern of their Effect on Early Caries
    Bennett Amaechi; Fiscal Year: 2005
    ..QLF data will be matched with their corresponding TMR data to determine the QLF parameters for lesions that were either completely remineralized or only arrested. ..